Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases.

Bibliographic Details
Title: Cryo-Imaging and Software Platform for Analysis of Molecular MR Imaging of Micrometastases.
Authors: Qutaish, Mohammed Q., Zhou, Zhuxian, Prabhu, David, Liu, Yiqiao, Busso, Mallory R., Izadnegahdar, Donna, Gargesha, Madhusudhana, Lu, Hong, Lu, Zheng-Rong, Wilson, David L.
Source: International Journal of Biomedical Imaging; 4/1/2018, p1-16, 16p
Subject Terms: MICROMETASTASIS, ANIMAL experimentation, COMPUTER software, EXPERIMENTAL design, INFLAMMATION, MAGNETIC resonance imaging, MICE, NECROSIS, RESEARCH evaluation, FLUORESCENT dyes, DIAGNOSIS, THERAPEUTICS
Abstract: We created and evaluated a preclinical, multimodality imaging, and software platform to assess molecular imaging of small metastases. This included experimental methods (e.g., GFP-labeled tumor and high resolution multispectral cryo-imaging), nonrigid image registration, and interactive visualization of imaging agent targeting. We describe technological details earlier applied to GFP-labeled metastatic tumor targeting by molecular MR (CREKA-Gd) and red fluorescent (CREKA-Cy5) imaging agents. Optimized nonrigid cryo-MRI registration enabled nonambiguous association of MR signals to GFP tumors. Interactive visualization of out-of-RAM volumetric image data allowed one to zoom to a GFP-labeled micrometastasis, determine its anatomical location from color cryo-images, and establish the presence/absence of targeted CREKA-Gd and CREKA-Cy5. In a mouse with >160 GFP-labeled tumors, we determined that in the MR images every tumor in the lung >0.3 mm2 had visible signal and that some metastases as small as 0.1 mm2 were also visible. More tumors were visible in CREKA-Cy5 than in CREKA-Gd MRI. Tape transfer method and nonrigid registration allowed accurate (<11 μm error) registration of whole mouse histology to corresponding cryo-images. Histology showed inflammation and necrotic regions not labeled by imaging agents. This mouse-to-cells multiscale and multimodality platform should uniquely enable more informative and accurate studies of metastatic cancer imaging and therapy. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Biomedical Imaging is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.
More Details
ISSN:16874188
DOI:10.1155/2018/9780349
Published in:International Journal of Biomedical Imaging
Language:English